Loading stock data…
TRAW
$1.32-0.04 (-3.28%)
Market OpenUpdated 3:41 PM EDT
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small-molecule oral product candidates for respiratory viral diseases and cancer.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Traws Pharma, Inc. in the Healthcare sector is trading at $1.32 with a market capitalization of $22M. Wall Street consensus targets $5.50 (2 analysts), implying a +315.1% move over the next 12 months. The stock is currently near its 52-week low of $1.00, remaining 29.9% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 30 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +315.1% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 30) — potential for technical mean-reversion
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$1.32
Potential Downside
0%
Whystock Fair Value$1.32
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small-molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are d...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$21.97M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.47
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
365.79%
Volume
Today's trading volume
243,767
Recent News
Sector Update: Healthcare Stocks Lower Late Afternoon
Healthcare stocks declined late Friday afternoon, with the NYSE Healthcare Index and the State Stree
Traws Pharma, Inc. (TRAW) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Traws Pharma, Inc. (TRAW) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Traws Pharma, Inc. Q4 2025 Earnings Call Summary
Moby summary of Traws Pharma, Inc.'s Q4 2025 earnings call
Traws Pharma Inc (TRAW) Q4 2025 Earnings Call Highlights: A Turnaround Year with Significant ...
Traws Pharma Inc (TRAW) reports a remarkable financial turnaround in 2025, driven by strategic financing and promising developments in its flu program.
hVIVO, Connecting Excellence, ACG Metals, Kodal Minerals, Ariana Resources, Sunda Energy
hVIVO PLC (AIM:HVO) has signed a deal with Traws Pharma to run an influenza human challenge trial in London. The contract coincides with a rebrand, bringing all its services under one roof. Connecting Excellence Group PLC (AQSE:XCE, OTCQB:XCELF) has been paid in Bitcoin for recruitment services, a first for a UK-listed recruiter. The payment of 0.516 BTC takes its total treasury holdings to just under 53 Bitcoin. ACG Metals Ltd (LSE:ACG, OTC:ACGAF) posted adjusted EBITDA of $76.3 million for 2025, with its Gediktepe mine in Turkey delivering strong margins. A transition to copper and zinc concentrate production is on track for mid-2026. Kodal Minerals (AIM:KOD) had a record month in March at its Bougouni Lithium Project in Mali, topping 10,900 tonnes of spodumene concentrate. A third export shipment departed on 12 April, taking cumulative exports to around 69,000 tonnes. Ariana Resources PLC (AIM:AAU, ASX:AA2, FRA:4A6) has appointed Michael Atkins as its new chair, as the company begins a broader transformation around its Dokwe Gold Project in Zimbabwe. Sunda Energy PLC (AIM:SNDA) has paid a $1.5 million deposit on its proposed New Zealand acquisition and filed for regulatory approval. The deal moves it a step closer to adding new energy assets in the region. Follow us and subscribe on YouTube, our social channels, and on proactiveinvestors.co.uk.